CMS Extends Temporary Medicare Coverage Program for GLP-1 Obesity Drugs

The Centers for Medicare & Medicaid Services (CMS) announced that its BALANCE model program, designed to provide temporary Medicare coverage for GLP-1 drugs to treat obesity, will not launch as scheduled on January 1, 2027. The delay effectively extends the current Medicare coverage approach for these medications. GLP-1 drugs have gained significant attention for weight loss treatment, but Medicare has historically faced restrictions on covering obesity medications. The BALANCE model was intended as a temporary framework to test coverage of these drugs for obesity within Medicare.

CMS BALANCE Model Program Delay

• ▪The Centers for Medicare & Medicaid Services (CMS) announced the delay of the BALANCE model program
• ▪The Centers for Medicare & Medicaid Services (CMS) BALANCE model will not launch as scheduled on January 1, 2027

Medicare Coverage for GLP-1 Obesity Drugs

• ▪The BALANCE model was designed to cover GLP-1 drugs for obesity in Medicare